Topic: Erasmus MC Cancer Institute

With a relatively simple test, urologists may be able to accurately determine in the future which patients will benefit from BCG bladder instillations. This is important because in 40 percent of patients, treatment is not successful, while treatment duration is lengthy and can cause unpleasant side effects.

American bladder cancer scientists have been awarded the prestigious R01 grant, together with urologist Dr. Tahlita Zuiverloon of the Erasmus MC Cancer Institute. The team will receive $3 million for research into the biology of chemotherapy resistance in bladder cancer.

A blood test can help to predict whether immunotherapy will be effective in patients with metastatic bladder cancer. This is evident from research by internist-oncologist Debbie Robbrecht from the Erasmus MC Cancer Institute.

If the expression ‘looking for a needle in a haystack’ applies to anyone, it is to Prof. John Martens of the Erasmus MC Cancer Institute. He and his team search for fragments of cancer in body fluids. These liquid biopsies teach them a lot about cancer patients and their tumors.

Internist and oncologist Stefan Sleijfer and hospital pharmacist Roelof van Leeuwen of Erasmus MC Cancer Institute are working closely together to make cancer therapies more effective. This is not only good for patients, but also for public coffers and for the environment. These efforts save the department of Internal Oncology about EUR 7 million per […]